| ||January 08, 2007|
Award Winning Harvard Diabetes Specialist Appointed to Help Advance Sernova's Sertolin Diabetes Therapy to Clinical Trials
| ||Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce that Dr. George King, Senior Vice President and Director of Research at Harvard Medical School's Joslin Diabetes Center, has accepted an appointment to Sernova's Scientific Advisory Board.|
One of the world's foremost diabetolgists, Dr. King has an extensive and successful history of conducting research into the causes, complications and treatment options of diabetes. Dr. David White, principal researcher for Sernova states, "With such an intricate understanding of the biology of diabetes, Dr. King will be an excellent advisor for our preclinical studies and be of great assistance during our application process to the FDA and other health regulators."
Dr. King commented, "This is a promising cellular therapy for treating diabetes so I look forward to assisting Sernova to advance the technology. Being an emerging technology, xenotransplantation needs to proceed with meticulous attention to accepted medical and research practises and I believe Sernova will follow these protocols closely."
About Dr. King
Dr. King received his medical degree from Duke University Medical School, completed residency training at the University of Washington Affiliated Hospitals in Seattle, and then completed research training at the National Institutes of Health in Bethesda Maryland. He has been at the Joslin Clinic and Harvard Medical School since 1981. He is currently the Director of Research and Head of the Section on Vascular Cell Biology at Joslin, and a Professor of Medicine at Harvard Medical School.
Dr. King has received numerous awards including the Donald Silver Excellence in Research Award from the Juvenile Diabetes Foundation, the Cogan Award from the Association for Research in Vision and Ophthalmology, the Stadie Memorial Award and Lectureship from the Philadelphia Affiliate of the American Diabetes Association, the Alcon Award for Vision Research, and the Annual Award for Excellence in Research from the Japan Society of Diabetic Complications.
Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.
This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
ON BEHALF OF THE BOARD
Justin Leushner, President
For further information contact:
TEL: (888) 318-7062
FAX: (250) 868-8493
THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
You can view the Next News Releases item: Mon Feb 5, 2007, Pre-Clinical Milestones for Sertolin Cell Replacement Technology: Insulin-Producing Cells Survive and Function without Anti-Rejection Drugs
You can view the Previous News Releases item: Tue Dec 19, 2006, Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology
You can return to the main News Releases page, or press the Back button on your browser.